LIGAND PHARMACEUTICALS INC 4
4 · LIGAND PHARMACEUTICALS INC · Filed Nov 21, 2003
Insider Transaction Report
Form 4
JOHNSON IRVING S
Director
Transactions
- Exercise/Conversion
Common Stock
2003-11-20$5.81/sh+8,118$47,186→ 31,047 total - Sale
Common Stock
2003-11-20$12.00/sh−8,118$97,416→ 22,929 total - Exercise/Conversion
Common Stock
2003-11-20$4.58/sh+1,527$6,998→ 24,456 total - Exercise/Conversion
Common Stock
2003-11-20$5.68/sh+1,583$8,996→ 24,512 total - Sale
Common Stock
2003-11-20$12.00/sh−1,583$18,996→ 22,929 total - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2003-11-20$12.00/sh−1,527$18,324→ 0 totalExercise: $4.58Exp: 2011-01-02→ Common Stock (1,527 underlying) - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2003-11-20$12.00/sh−1,583$18,996→ 0 totalExercise: $5.68Exp: 2012-01-02→ Common Stock (1,583 underlying) - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2003-11-20$12.00/sh−8,118$97,416→ 0 totalExercise: $5.81From: 1996-05-17Exp: 2005-05-17→ Common Stock (8,118 underlying) - Sale
Common Stock
2003-11-20$12.00/sh−1,527$18,324→ 22,929 total
Footnotes (2)
- [F1]The option becomes exercisable in twelve successive equal monthly installments upon completion of each calendar month of service beginning 1/31/01.
- [F2]The option becomes exercisable in twelve successive equal monthly installments upon completion of each calendar month of service beginning 1/31/02.